New research shows the diabetes drug empagliflozin protects against experimental abdominal aortic aneurysm by reshaping the gut microbiome and strengthening the intestinal barrier.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.